Phase II Study of Revumenib for Leukemia with HOX Gene Upregulation
This study is testing a drug called revumenib to see if it can help control certain types of leukemia. These leukemias are linked to an increase in specific genes called HOX genes. You might be able to join if you are at least 12 years old, weigh 40kg or more, and have acute leukemia that has come back or not responded to previous treatments. Your leukemia must also have certain genetic changes that cause HOX gene upregulation. The main goal is to look at the safety of revumenib and any side effects you might experience over about one year. The study is currently unclear on its recruitment status, but plans to enroll 40 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It is a Phase II study and plans to enroll 40 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and side effects will be measured throughout the study, which is expected to average one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Ghayas Issa, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0